...
首页> 外文期刊>Current opinion in critical care >Management strategies for acute spinal cord injury: Current options and future perspectives
【24h】

Management strategies for acute spinal cord injury: Current options and future perspectives

机译:急性脊髓损伤的治疗策略:当前的选择和未来的前景

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE OF REVIEW: Spinal cord injury is a devastating acute neurological condition with loss of function and poor long-term prognosis. This review summarizes current management strategies and innovative concepts on the horizon. RECENT FINDINGS: The routine use of steroids in patients with spinal cord injuries has been largely abandoned and considered a 'harmful standard of care'. Prospective trials have shown that early spine stabilization within 24h results in decreased secondary complication rates. Neuronal plasticity and axonal regeneration in the adult spinal cord are limited due to myelin-associated inhibitory molecules, such as Nogo-A. The experimental inhibition of Nogo-A ameliorates axonal sprouting and functional recovery in animal models. SUMMARY: General management strategies for acute spinal cord injury consist of protection of airway, breathing, oxygenation and control of blood loss with maintenance of blood pressure. Unstable spine fractures should be stabilized early to allow unrestricted mobilization of patients with spinal cord injuries and to decrease preventable complications. Steroids are largely considered obsolete and have been abandoned in clinical guidelines. Nogo-A represents a promising new pharmacological target to promote sprouting of injured axons and restore function. Prospective clinical trials of Nogo-A inhibition in patients with spinal cord injuries are currently under way.
机译:审查目的:脊髓损伤是一种破坏性的急性神经系统疾病,功能丧失且长期预后不良。这篇综述总结了当前的管理策略和创新概念。最近的发现:脊髓损伤患者常规使用类固醇已被放弃,被认为是“有害的护理标准”。前瞻性试验表明,在24小时内尽早使脊柱稳定会降低继发并发症的发生率。由于髓鞘相关的抑制性分子(例如Nogo-A),成人脊髓中的神经元可塑性和轴突再生受到限制。在动物模型中,Nogo-A的实验抑制作用可改善轴突发芽和功能恢复。摘要:急性脊髓损伤的一般管理策略包括保护气道,呼吸,充氧和控制血压并维持血压。不稳定的脊柱骨折应尽早稳定,以使脊髓损伤患者能够不受限制地活动,并减少可预防的并发症。类固醇在很大程度上被认为是过时的,在临床指南中已被放弃。 Nogo-A代表了一种有希望的新药理学靶标,可促进受伤轴突的发芽并恢复功能。目前正在开展Nogo-A抑制治疗脊髓损伤患者的前瞻性临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号